Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas, TX. Public Ventures Discovery DayDate: Tuesday, March 19, 2024Presentation: 2:30 PM CSTLocation: Pecan Room, Old Parkland, 3819 Maple Avenue, Dallas TX 75219 A video replay of the fireside chat will be available shortly after the conclusion of the event on the Investors and Media section of the company’s website at www.gaintherapeutics.com. Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, (NASDAQ: MDBH), is the first invite-only investor community and self-clearing broker-dealer platform dedicated to backing visionary public companies with the potential to become market lead
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseGlobeNewswire
- Gain Therapeutics, Inc. (NASDAQ: GANX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.MarketBeat
- Hansa Biopharma interim report January-March 2024 [Yahoo! Finance]Yahoo! Finance
GANX
Earnings
- 11/14/23 - Beat
GANX
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- GANX's page on the SEC website